Hong Kong-listed Chinese Legend Holdings’s venture capital unit Legend Capital has led a 700 million yuan ($107 million) Series E round funding in MicuRx Pharmaceuticals, Inc., a Chinese clinical-stage biopharma firm specialising in antimicrobial therapeutics, the investee said in a WeChat post on Monday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
